Literature DB >> 3030531

Patient age, histologic features, and length of survival in patients with glioblastoma multiforme.

P C Burger, S B Green.   

Abstract

Histologic sections from 71 patients with glioblastoma multiforme were reviewed to identify histologic prognostic factors and to explain the significantly shorter survival in older patients. Slides were studied for 14 histologic variables from a group of 35 patients aged less 45 years and from 36 patients aged 65 years or more. The relation of these histologic factors to the length of survival and age group was then investigated. The results document the marked histologic and cytologic heterogeneity of the glioblastoma and reaffirm the importance of necrosis as a prognostic factor. The results further suggest that patients whose glioblastomas contained microcysts, pseudopalisading, cells with astrocytic differentiation, and large areas of better differentiated glioma, did better than those patients whose lesions were homogeneously composed of small cells or whose lesion had a small median nuclear size. The study reaffirmed the strong (P less than 0.0001) negative relationship between advancing age and duration of postoperative survival. The presence of necrosis, a smaller standard deviation of nuclear size, the extent of vascular proliferation, the absence of well differentiated neoplastic fibrillary astrocytes, and neoplasms composed homogeneously of small cells were related to patient age and offered a possible explanation for at least part of the observed age effect. However, the strong relation between age and survival remained significant when adjusted for other variables, and the effect of age must rest largely on factors other than those detected in this morphologic study.

Entities:  

Mesh:

Year:  1987        PMID: 3030531     DOI: 10.1002/1097-0142(19870501)59:9<1617::aid-cncr2820590916>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  77 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 2.  Molecular heterogeneity of glioblastoma and its clinical relevance.

Authors:  Katalin Eder; Bernadette Kalman
Journal:  Pathol Oncol Res       Date:  2014-08-27       Impact factor: 3.201

3.  Glioblastoma--the consequences of advanced patient age on treatment and survival.

Authors:  Andreas M Stark; Jürgen Hedderich; Janka Held-Feindt; H Maximilian Mehdorn
Journal:  Neurosurg Rev       Date:  2006-11-21       Impact factor: 3.042

4.  Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Authors:  Andrea Pirzkall; Colleen McGue; Suja Saraswathy; Soonmee Cha; Raymond Liu; Scott Vandenberg; Kathleen R Lamborn; Mitchel S Berger; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

5.  Brain tumor survival: results from the National Cancer Data Base.

Authors:  T S Surawicz; F Davis; S Freels; E R Laws; H R Menck
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

6.  Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma.

Authors:  Lola B Chambless; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson
Journal:  J Neurooncol       Date:  2011-08-11       Impact factor: 4.130

7.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

Authors:  C K Goldman; J Kim; W L Wong; V King; T Brock; G Y Gillespie
Journal:  Mol Biol Cell       Date:  1993-01       Impact factor: 4.138

Review 8.  The basis for current treatment recommendations for malignant gliomas.

Authors:  H A Fine
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Authors:  Suja Saraswathy; Forrest W Crawford; Kathleen R Lamborn; Andrea Pirzkall; Susan Chang; Soonmee Cha; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-09-23       Impact factor: 4.130

10.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.